AbbVie (NYSE:ABBV) Shares Down 3.8% – What’s Next?

AbbVie Inc. (NYSE:ABBV) shares dropped 3.8% on Monday . The stock traded as low as $217.86 and last traded at $220.5710. Approximately 8,868,660 shares changed hands during trading, an increase of 45% from the average daily volume of 6,101,917 shares. The stock had previously closed at $229.31.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABBV. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the stock from $170.00 to $270.00 in a research note on Wednesday, September 17th. Erste Group Bank lowered shares of AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a report on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Finally, Guggenheim raised their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $245.84.

AbbVie Trading Down 3.8%

The business’s 50 day moving average price is $226.54 and its two-hundred day moving average price is $214.39. The stock has a market cap of $389.83 billion, a P/E ratio of 167.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the business posted $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of AbbVie during the second quarter valued at approximately $4,288,200,000. Wellington Management Group LLP increased its position in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Laurel Wealth Advisors LLC lifted its position in AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after acquiring an additional 3,666,521 shares during the period. Finally, Vanguard Group Inc. boosted its stake in AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.